References
- Curtis C. G., Hughes H. M., Powell G. M. The use of isolated perfused organs. Metabolism of Xenobiotics, J. W. Gorrod, H. Oelschlager, J. Caldwell. Taylor & Francis, Philadelphia 1988; 295–302
- Dulik D. M., Fenselau C. Use of immobilized enzymes in drug metabolism studies. FASEB Journal 1988; 2: 2235–2240
- Eison M. S., Eison A. S. Buspirone as a mid-brain modulator: anxiolysis unrelated to the traditional benzodiazepine mechanisms. Drug Development Research 1984; 4: 109–119
- Eison A. S., Temple D. L. Buspirone: a review of its pharmacology and current perspectives on its mechanism of action. American Journal of Medicine 1986; 80(3B)1–9
- Eison A. S., Eison M. S., Stanley M., Riblet L. A. Serotoninergic mechanisms in the behavioral effects of buspirone and gepirone. Pharmacological Biological Behaviour 1986; 24: 701–707
- Fry J. R. Metabolism of xenobiotics in isolated cells: comparison with other in vitro systems and in vivo. Metabolism of xenobiotics, J. W. Gorrod, H. Oelschlager, J. Caldwell. Taylor & Francis, Philadelphia 1988; 303–389
- Gibson G. G. Purified enzymes as biological models for drug metabolism. Drug metabolism: from molecules to Man, D. J. Benford, J. W. Bridges, G. G. Gibson. Taylor & Francis, Philadelphia 1987; 379–391
- Goa K. L., Ward A. Buspirone: a preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986; 32: 114–129
- Goldberg H. L. Buspirone hydrochloride: a unique new anxiolytic agent. Pharmacokinetics, clinical pharmacology, abuse potential and clinical efficacy. Pharmacotherapy 1984; 4: 315–324
- Jajoo H. K., Mayol R. F., Labudde J. A., Blair I. A. Metabolism of the antianxiety drug buspirone in the rat. Drug Metabolism and Disposition 1989 a; 17: 625–633
- Jajoo H. K., Mayol R. F., Labudde J. A., Blair I. A. Metabolism of the antianxiety drug buspirone in human subjects. Drug Metabolism and Disposition 1989 b; 17: 634–640
- Meredith M. J. Rat hepatocytes prepared without collagenase: prolonged retention of differentiated characteristics in culture. Cell Biology and Toxicology 1988; 4: 405–425
- Moldeus P. Comparison of model systems for metabolism. Drug Metabolism: from Molecules to Man, D. J. Benford, J. W. Bridges, G. G. Gibson. Taylor & Francis, Philadelphia 1987; 309–316
- Newton R. E., Marunycz J. D., Alderdice M. T., Napoliello M. J. Review of the side effect profile of buspirone. American Journal of Medicine 1986; 80(3B)17–21
- Remmer H., Griem H., Schenkman J. B., Estabrook R. W. Methods for the elevation of hepatic microsomal mixed function oxidase levels and cytochrome P-450. Methods in Enzymology 1967; 10: 703–708
- Riblet L. A., Eison A. S., Eison M. S., Taylor D. P., Temple D. L., Vandermaelen C. P. Neurophysiology of buspirone. Psychopathology 1984; 17: 69–78, (Suppl. 3)
- Schuckit M. A. Clinical studies of buspirone. Psychopathology 1984; 17: 61–68, (Suppl. 3)
- Taylor D. P. Buspirone: a new approach to the treatment of anxiety. FASEB Journal 1988; 2: 2445–2452
- Taylor D. P., Allen L. E., Becker J. A., Crane M., Hyslop D. K., Riblet L. A. Changing concepts of the biochemical action of the anxioselective drug buspirone. Drug Development Research 1984; 4: 95–108
- Tee L. G. B., Seddon T., Boobis A. R., Davies D. S. Drug metabolizing activity of freshly isolated human hepatocytes. British Journal of Pharmacology 1985; 19: 279–294
- Trulson M. E., Trulson T. J. Buspirone decreases the activity of serotonin containing neurons in the dorsal raphe in free-moving cats. Neuropharmacology 1986; 25: 1263–1266
- Yevich J. P., New J. S., Smith D. W., Lobeck W. G., Catt J. D., Minielli J. L., Eison M. S., Taylor D. P., Riblet L. A., Temple D. L. Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)-and (benzisoxathiazil-3-yl)-piperazine derivatives as potential antipsychotic agents. Journal of Medicinal Chemistry 1986; 29: 359–369